Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Diana Stichel"'
Autor:
Christine Heller, Christoph Königs, Esra Kaya, Stephan Schultze-Strasser, Aleksander Orlowski, Diana Stichel
Publikováno v:
Hamburger Hämophilie Symposion Hamburg, Germany.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d096b30c0546bfebbed79a7207a0571b
https://doi.org/10.1055/s-0040-1721576
https://doi.org/10.1055/s-0040-1721576
Autor:
Christoph Königs, Christine Heller, Stephan Schultze-Strasser, Thomas Klingebiel, Aleksander Orlowski, Anja Schmidt, Diana Stichel
Publikováno v:
Hamburger Hämophilie Symposion Hamburg, Germany.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::582e831b750b70ac5316f05d73c4e35e
https://doi.org/10.1055/s-0040-1721603
https://doi.org/10.1055/s-0040-1721603
Autor:
Diana Stichel, Christoph Königs, Aleksander Orlowski, Christine Heller, Thomas Klingebiel, Sonja Neimanis, Dirk Schwabe, Stephan Schultze-Strasser, J. Kahle, Anja Schmidt
Publikováno v:
Hamburger Hämophilie Symposion Hamburg, Germany.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::769423bd5e84300f3908534086b4eabf
https://doi.org/10.1055/s-0040-1721602
https://doi.org/10.1055/s-0040-1721602
Autor:
Kerstin Brettschneider, J. Kahle, Anja Schmidt, Dirk Schwabe, Christoph Königs, Diana Stichel, Aleksander Orlowski
Publikováno v:
Journal of Thrombosis and Haemostasis. 16:2223-2232
Essentials There is still a need for novel therapeutic approaches for hemophilia A patients with inhibitors. A factor VIII domain was used as the targeting moiety for elimination of FVIII-specific B cells. The immunodominant C2 domain was fused to ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6030caff27cc918b598af9893bc223d
https://doi.org/10.1111/jth.14273
https://doi.org/10.1111/jth.14273
Autor:
Christoph Königs, Diana Stichel, M. Beilfuß, Anja Schmidt, Aleksander Orlowski, Christine Heller, E. Kaya, Thomas Klingebiel, J. Hartmann
Publikováno v:
Science meets clinical practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6437c54b7000d0c2a177fd07090a70bf
https://doi.org/10.1055/s-0039-1680121
https://doi.org/10.1055/s-0039-1680121
Publikováno v:
Science meets clinical practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ed92165a7ae5e959cb73871ce70aa08
https://doi.org/10.1055/s-0039-1680164
https://doi.org/10.1055/s-0039-1680164
Autor:
Aleksander Orlowski, Christine Heller, Diana Stichel, M. Beilfuss, Anja Schmidt, D. Schwabe, Nadia P. Ewing, Christoph Königs, Thomas Klingebiel, J. Hartmann
Publikováno v:
Science meets clinical practice.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1defcaf0ffde3e92daa801136c68f294
https://doi.org/10.1055/s-0039-1680120
https://doi.org/10.1055/s-0039-1680120
Autor:
Ali Kabiri, Diana Stichel, Joerg Kahle, Pete Lollar, John F. Healey, Karin Becker-Peters, Anja Naumann, Anna Katharina Scherger, Aleksander Orlowski, Christoph Königs, Dirk Schwabe, Kerstin Brettschneider
Publikováno v:
Thrombosis and Haemostasis. 113:396-405
SummaryThe most serious complication in today’s treatment of congenital haemophilia A is the development of neutralising antibodies (inhibitors) against factor VIII (FVIII). Although FVIII inhibitors can be eliminated by immune tolerance induction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1bdb59abaf14a6fcfb2cc2aa1ff2d3a
https://doi.org/10.1160/th14-01-0101
https://doi.org/10.1160/th14-01-0101
Autor:
Pete Lollar, Aleksander Orlowski, John F. Healey, Diana Stichel, Christoph Königs, Ernest T. Parker, Manuela Krause, Dirk Schwabe, Marc Jacquemin, Joerg Kahle, Andreas Tiede
Publikováno v:
Blood. 130(6)
Several studies showed that neutralizing anti-factor VIII (anti-fVIII) antibodies (inhibitors) in patients with acquired hemophilia A (AHA) and congenital hemophilia A (HA) are primarily directed to the A2 and C2 domains. In this study, the frequency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c9b8f1bdf5a49c3233d835033b68328
https://pubmed.ncbi.nlm.nih.gov/28507083
https://pubmed.ncbi.nlm.nih.gov/28507083
Autor:
Sharyne Donfield, J. Kahle, Diana Stichel, Christoph Königs, Dirk Schwabe, Aleksander Orlowski, Ernest T. Parker, John F. Healey, Jan Astermark, Erik Berntorp, Pete Lollar
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 23(2)
Introduction: The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is currently the most serious complication for patients with haemophilia A undergoing FVIII replacement therapy. Several genetic factors hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3e7acc381c26985b279e5b85afe7e1
https://pubmed.ncbi.nlm.nih.gov/27862687
https://pubmed.ncbi.nlm.nih.gov/27862687